Physician profile

Karl E Wolfe

Physician Assistant · Jonesville, MI

NPI 1013932391

$9,780.01

in general payments reported to CMS, 2019-2025

41 companies · $1,778 in 2025

The $1,778 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,594.14
Education$99.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $1,487.09 2021-2025 Ozempic, Wegovy, Rybelsus
Otsuka America Pharmaceutical, INC. $779.48 2022-2025 Rexulti
Abbvie INC. $759.14 2021-2025
Astrazeneca Pharmaceuticals Lp $728.81 2021-2025 Airsupra, Breztri, Farxiga
Lilly USA, LLC $681.68 2021-2025 Mounjaro, Jardiance, Zepbound
Pfizer INC. $662.48 2021-2025
Glaxosmithkline, LLC. $651.30 2021-2025 Trelegy Ellipta, Arexvy, Shingrix
Merck Sharp & Dohme LLC $410.47 2021-2025 Gardasil 9, Vaxneuvance, Capvaxive
Actelion Pharmaceuticals US, INC. $374.26 2021-2025 Opsumit, Uptravi
Amgen INC. $351.49 2021-2025 Otezla, Repatha, Evenity
Bayer Healthcare Pharmaceuticals INC. $331.52 2021-2025
Janssen Pharmaceuticals, INC $313.82 2021-2022
Lundbeck LLC $240.07 2022-2025 Rexulti
Axsome Therapeutics, INC. $215.62 2025 Auvelity
Nestle Healthcare Nutrition INC. $206.20 2021-2023
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Corcept Therapeutics $182.32 2021-2025 Korlym
Boehringer Ingelheim Pharmaceuticals, INC. $152.02 2021-2022
Sanofi-Aventis U.S. LLC $111.57 2021-2022
Sumitomo Pharma America, INC. $101.70 2024-2025 Gemtesa
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $93.57 2022-2025 Caplyta
Kowa Pharmaceuticals America, INC. $91.02 2021-2025 Zoryve, Livalo, Seglentis
Insulet Corporation $87.41 2022-2023 Omnipod
Biohaven Pharmaceuticals, INC. $84.98 2021
Takeda Pharmaceuticals U.S.A., INC. $78.36 2021-2022
Exact Sciences Corporation $69.61 2025 The Cologuard Plus Collection Kit, Cologuard Collection Kit
Dexcom, INC. $67.23 2024-2025 Dexcom G6 Transmitter
Eisai INC. $58.66 2021-2024
Novartis Pharmaceuticals Corporation $57.93 2021-2023
Amarin Pharma, INC. $57.23 2021
Teva Pharmaceuticals USA, INC. $53.43 2021-2022
Biohaven Pharmaceutical Holding Company Ltd. $50.87 2022
Vanda Pharmaceuticals INC. $33.78 2025 Fanapt
Electromed, INC. $25.94 2021
Mylan Specialty L.P. $20.73 2024 Yupelri
Tonix Medicines, INC. $19.08 2025 Tonmya
Cognoa, INC. $18.24 2022
Daiichi Sankyo INC. $17.04 2021
Sanofi Pasteur INC. $14.57 2023
Astellas Pharma US INC $14.29 2021
E.R. Squibb & Sons, L.L.C. $12.65 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $12.35 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Karl E Wolfe

$9,780.01

in general payments reported 2019-2025

Years
2021-2025
Top company
Novo Nordisk INC
Context
The $1,778 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).

https://glasscript.com/doctor/10951790/karl-e-wolfe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.